XGN

Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on the proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen\'s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.

Exagen Inc. (XGN) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) C (2.4) B (3.2) B- (3.1) C+ (2.6) B- (2.9)
2026-11-08 B- (3.0) C (2.5) C (2.5) B (3.5) C+ (2.6) C+ (2.8)
2026-11-01 B- (3.0) C (2.4) C+ (2.5) A- (3.9) C+ (2.7) B- (2.9)
2026-10-25 B- (3.0) C (2.4) C+ (2.5) A- (3.9) C+ (2.6) B- (2.9)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe